ZLWH-67
ZLWH-67 is a β-Carboline derivative and Antibacterial agent. ZLWH-67 inhibits DNA synthesis, suppresses biofilm formation, and increases reactive oxygen species (ROS) levels. ZLWH-67 exhibits potent in vitro antibacterial activity against MRSA (MIC = 0.5-4 μg/mL), S. epidermidis (MIC = 4 μg/mL), E. faecalis (MIC = 4-8 μg/mL), and S. pneumoniae (MIC = 16 μg/mL). ZLWH-67 displays anti-MRSA effects in murine skin and pneumonia infection models.
For research use only. We do not sell to patients.
- CAS No.: 3083425-49-1
- Formula: C24H20N4O4
- Molecular Weight:428.44
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All DNA/RNA Synthesis Isoforms
More
Biological Activity
ZLWH-67 (24 h) exhibits potent in vitro antibacterial activity against MRSA (MIC = 0.5-4 μg/mL), S. epidermidis (MIC = 4 μg/mL), E. faecalis (MIC = 4-8 μg/mL) and S. pneumoniae (MIC = 16 μg/mL); its MBC against MRSA USA300 is 4 μg/mL, and it shows no activity against the tested Gram-negative bacteria or fungi[1].
ZLWH-67 (16-256 μg/mL; 1 h) shows no hemolytic toxicity to sheep red blood cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
ZLWH-67 (100 mg/kg/day) significantly improves survival, reduces MRSA bacterial burden, lowers proinflammatory cytokine levels, and mitigates tissue damage in mouse lethal and sublethal pneumonia infection models[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 6−8 weeks old)[1]
-
Dosage:0.4 mg/kg
-
Administration:topical; twice daily; 4 days
-
Result:Reduced bacterial burden in skin tissues (log10 CFU/0.1 g tissue decreased relative to controls, P=0.0364).
Promoted wound closure relative to controls.
Significantly reduced levels of proinflammatory cytokines TNF-α, IL-6, and IL-1β in skin tissues (P=0.0009, P=0.0239, P=0.0201 respectively).
Alleviated skin tissue pathology including necrosis, inflammatory exudate, and hemorrhage.
-
Animal Model:C57BL/6 (female, 6−8 weeks old)[1]
-
Dosage:100 mg/kg/day
-
Administration:daily
-
Result:In the lethal pneumonia model, significantly improved mouse survival rate relative to controls.
Alleviated infection-related clinical symptoms and promoted body weight recovery relative to controls.
In the sublethal pneumonia model, reduced bacterial burden in lung tissues (log10 CFU/mL tissue decreased relative to controls, P=0.0047).
Significantly reduced levels of proinflammatory cytokines TNF-α, IL-6, and IL-1β in lung tissues (P=0.0008, P=0.0016, P<0.0001 respectively).
Alleviated lung tissue pathology including alveolar wall thickening, epithelial desquamation, inflammatory infiltration, and hemorrhage.
Chemical Information
-
CAS No. 3083425-49-1
-
Molecular Weight 428.44
-
Formula C24H20N4O4
-
SMILES
O=C(C1=CC2=C(C=C1)C3=C(C(NC(C4CC4)=O)=NC=C3)N2)NCC5=CC=C(OCO6)C6=C5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
ZLWH-67 Related Classifications
Cat. No.: HY-182022
Powered by Bioz
- ZLWH-67
- 3083425-49-1
- ZLWH67
- ZLWH 67
- Bacterial
- Reactive Oxygen Species (ROS)
- Drug Derivative
- DNA/RNA Synthesis
- oxidative stress
- DNA synthesis
- MSSA
- energy metabolism
- mouse pneumonia infection models
- biofilm formation
- cell membrane integrity
- cytoplasmic DNA leakage
- mouse skin infection models
- MRSA
- Inhibitor
- inhibitor
- inhibit